SML2498
Vatalanib dihydrochloride
≥98% (HPLC)
别名:
1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine dihydrochloride, CGP 79787 dihydrochloride, CGP 79787D dihydrochloride, N-(4-Chloroanilino)-4-(pyridin-4-ylmethyl)phthalazin-1-amine dihydrochloride, PTK 787 dihydrochloride, PTK787 dihydrochloride, ZK 222584 dihydrochloride, ZK-222584 dihydrochloride, ZK222584 dihydrochloride
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H15ClN4 · 2HCl
化学文摘社编号:
分子量:
419.73
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
InChI
1S/C20H15ClN4.2ClH/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14;;/h1-12H,13H2,(H,23,25);2*1H
SMILES string
ClC(C=C1)=CC=C1NC2=NN=C(CC3=CC=NC=C3)C4=CC=CC=C42
InChI key
AZUQEHCMDUSRLH-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
Orally active anti-angiogenic agent that targets receptor tyrosine kinases VEGFR1/2/3 (FLT-1/KDR/FLT-4), PDGFRβ, c-KIT and c-FMS.
Vatalanib (PTK787, ZK 222584, CGP 79787D, CGP 79787 succinate) is an orally active anilinophthalazine derivative that exerts its anti-angiogenic efficacy by targeting receptor tyrosine kinase (RTK) VEGFR (VEGFR1/2 IC50 = 54/39 nM; IC50 ∼30 nM against 100 ng/mL VEGF-C-induced VEGFR3 autophosphorylation in MEVCs) and, to a less extent, PDGFRβ, c-kit, c-fms (IC50 = 364, 600, 567 nM, respectively) in an ATP-competitive manner with much reduced or no potency toward >90 other kinases. Typical dosing ranges: 0.1-10 μM in cultures, 5 nM-200 μM (zebrafish) and 30-100 mg/kg (mice & rats via po. or ip) in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持